Tom McFarlane

Tom McFarlane
Clinical Lecturer
Location: PHR 5008
Phone: 519-888-4567 x21370


Dr. Tom McFarlane teaches oncology, internal medicine, and immunology topics to the undergraduate students at the School of Pharmacy. He has a particular interest in GI, lung, and prostate cancers, and conducts practice based research in these settings which includes exploring ways of improving supportive care regimens for patients and the impact of supportive care on overall outcomes. He is also interested in qualitative research examining patient attitudes toward cancer care.

Research Interests

  • Impact of pharmacist interventions on patient safety and adherence in oncology
  • Complementary and alternative medicine in oncology
  • Usage patterns of oncology and supportive care agents
  • Cancer immunotherapy and vaccines
  • Biosimilars in oncology
  • Clinical Pharmacy and Pharmacy Practice

Scholarly Research

Dr. McFarlane has several years of experience as a clinician in the oncology setting. He has a clinical, research, and student mentorship role at the Odette Cancer Centre at Sunnybrook Health Sciences in Toronto. His research interests include examining the utilization of pharmacists to deliver enhanced care to patients with cancer, the use of technology and apps to support cancer treatment, optimization of patterns of use of supportive care medications in oncology, and the development of systematic methods to manage drug interactions in oncology.


  • 2011 PharmD (Idaho State University)
  • 1996 BScPhm (University of Toronto)


  • Prof. McFarlane sits on the Assessment and Petitions Committees at the school and the Advisory Committee on Research Space.
  • He is also a member of the Canadian Association of Pharmacy in Oncology (CAPhO) Education Committee and the CAPhO Undergraduate Education Subcommittee.
  • In addition to these roles, he is the Chair of the CAPhO Research Committee and a member of the CAPhO Board of Directors, and is a member of the Cancer Care Ontario Genitourinary Cancers Site Group Formulary Advisory Committee.


  • PHARM 320 - Integrated Patient Focused Care 5
    • Taught in 2019, 2020, 2021, 2022, 2023
  • PHARM 321 - Integrated Patient Focused Care 6
    • Taught in 2021, 2022, 2023, 2024
  • PHARM 377 - Drug-Induced Disease
    • Taught in 2019, 2020, 2021, 2022
  • PHARM 464 - Advanced Therapeutic Concepts in Oncology
    • Taught in 2019, 2020, 2021, 2022, 2023
  • PHARM 475 - Advanced Pharmacotherapeutics in the Ambulatory Care Setting
    • Taught in 2019

* Only courses taught in the past 5 years are displayed.

Selected/Recent Publications

  • Kim YJ, Oremus M, Chan H, McFarlane T, Fearon D, Horton S. Factors affecting treatment selection and overall survival for first-line EGFR-TKI therapy in non-small-cell lung cancer. J Comp Eff Res 2021 [Article in press].
  • K Ellis, K Grindrod, S Tully, T McFarlane, KKW Chan, WWL Wong. Understanding the feasibility of implementing CAR T-cell therapies from a Canadian perspective. Healthc Policy 2020 (Article in press).
  • Patel T, Hasan S, Chang F, McFarlane T. Controlled substances in hospices after patient death: A cross-sectional survey. International Journal of Clinical Pharmacy 2020; [E-Pub ahead of print].
  • YJ Kim, M Oremus, HH Chen, T McFarlane, D Shah, S Horton. Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Future Oncology 2020; [E-Pub ahead of print].
  • JJ Kim, T McFarlane, S Tully, WWL Wong. Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma in Canada: a cost-utility analysis. The Oncologist 2020;25(3):512-519.
  • McFarlane T, Rehman N, Wang K, Lee J, Carter C. Cutaneous Toxicities of New Targeted Cancer Therapies: Must Knows for Diagnosis, Management, and Patient-Proxy Empowerment. Ann Palliat Med 2020;9(3):1296-1306.
  • S Tully, Z Feng, K Grindrod, T McFarlane, KKW Chan, WWL Wong. Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model. JCO Clin Cancer Inform 2019; [Epub ahead of print].
  • Richard CL, Lillie E, Mathias K, McFarlane T. Peer review of teaching in a Canadian pharmacy school: attitudes and impact on teaching practice. Am J Pharm Educ 2019;83(6):1290-1299.
  • McKenzie E, Chan D, Parsafar S, Razvi Y, Rico V, Pasetka M, DeAngelis C, McFarlane T, Chow C. Evolution of antiemetic studies for radiation-induced nausea and vomiting within a specialized cancer centre. Support Care Cancer 2019; 27(9):3245-3252:
  • Dubinsky S, Thawer A, McLeod AG, McFarlane TRJ, Emmenegger U. Management of anticoagulation in patients with metastatic castration–resistant prostate cancer receiving abiraterone + prednisone. Support Care Cancer 2019; 27(9):3209-3217.
  • McKenzie E, Zaki P, Raman S, Olson R, McFarlane T, DeAngelis C, Chan S, Pidduck W, Razvi Y, Bushehri A, Chow E. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines. Support Care Cancer 2019; 27(3):783-791.
  • Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak K. ASCO, NCCN, MASCC/ESMO: A Comparison of Antiemetic Guidelines for the Treatment of Chemotherapy Induced Nausea and Vomiting in Adult Patients. Support Care Cancer 2019; 27(1):89-95.
  • Cowley EC, McFarlane TR. Treatment options for patients with mantle cell lymphoma post-transplantation: A scoping review of the literature. Eur J Oncol Pharm 2018; 1(4): e0006.
  • Zargar M, McFarlane T, Chan KKW, Wong WWL. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. The Oncologist 2017; 23(2):225-233. doi: 10.1634/theoncologist.2017-0277.